Table IV –

Participants’ perception of the bleeding pattern experienced within 12 weeks of using a copper intrauterine system releasing 5, 20 or 40 μg of ulipristal acetate per day

	5 μg UPA/d (n= 8)	20 μg UPA/d (n= 10)	40 μg UPA/d (n= 9)
Number of periods experienced compared to usual – n (%)
Fewer	1 (12.5)	-	3 (33.3)
No change	7 (87.5)	9 (90)	6 (66.7)
More	-	1 (10)	-
Number of bleeding days experienced compared to usual – n (%)
Fewer	1 (12.5)	2 (20)	4 (44.4)
No change	6 (75)	5 (50)	5 (55.6)
More	1 (12.5)	3 (30)	-
Amount of bleeding experienced compared to usual – n (%)
Decreased a lot	1 (12.5)	3 (30)	3 (33.3)
Decreased some	3 (37.5)	5 (50)	4 (44.4)
No change	2 (25)	1 (10)	2 (22.2)
Increased some	2 (25)	1 (10)	-
Increased a lot	-	-	-
Satisfaction with overall bleeding pattern with the Cu-UPA-IUS use – n (%)
Extremely satisfied	1 (12.5)	3 (30)	3 (33.3)
Satisfied	5 (62.5)	7 (70)	6 (66.7)
Neutral	2 (25)	-	-
Dissatisfied /Extremely dissatisfied	-	-	-

UPA: Ulipristal acetate; Cu-UPA-IUS: copper intrauterine system releasing ulipristal

Per protocol population includes all participants who completed 12 weeks of intrauterine system use (n=27)